Welcome to our dedicated page for Vanda Pharma news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharma stock.
Vanda Pharmaceuticals Inc. (VNDA) is a biopharmaceutical innovator developing therapies for complex medical conditions with limited treatment options. This news hub provides investors and healthcare professionals with essential updates on the company's clinical advancements, regulatory milestones, and strategic initiatives.
Access real-time information about VNDA's sleep-wake disorder treatments, psychiatric therapies, and neurology pipeline. Our curated collection includes FDA decision updates, clinical trial results, financial earnings reports, and partnership announcements – all critical for understanding the company's market position.
Bookmark this page for streamlined tracking of Vanda's progress in antisense oligonucleotide research and commercialization efforts. Regular updates ensure you stay informed about HETLIOZ developments, Fanapt market performance, and emerging therapies in the company's clinical pipeline.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced that the FDA granted Orphan Drug Designation for VPO-227, a treatment for cholera. Despite low U.S. incidence, cholera poses significant global health risks, causing 21,000 to 143,000 deaths annually. VPO-227 blocks the CFTR ion channel, a key player in cholera-induced fluid loss. This designation offers benefits like tax credits and marketing exclusivity. Vanda plans to submit an Investigational New Drug (IND) application in 2023, exploiting the FDA's Tropical Disease Priority Review Voucher Program.
Vanda Pharmaceuticals (Nasdaq: VNDA) and OliPass Corporation have announced a collaboration to develop antisense oligonucleotide (ASO) therapeutics using OliPass' modified peptide nucleic acids. This partnership aims to enhance gene expression modulation in diseases with genetic underpinnings. Vanda has identified two ASO targets validated in disease models, focusing on a rare orphan condition and immuno-oncological diseases. The collaboration seeks to advance preclinical findings to clinical testing, leveraging OliPass' OPNA technology for improved therapeutic delivery.
Vanda Pharmaceuticals (NASDAQ: VNDA) will participate in the H.C. Wainwright Global Investment Conference in New York City on September 14, 2022, at 8:30 a.m. Eastern Time. Investors can access the live corporate presentation on Vanda's official website. The company is focused on developing innovative therapies for high unmet medical needs. An archived version of the presentation will be available for approximately 30 days after the conference.
On September 7, 2022, Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced the opportunity for an FDA hearing regarding its Supplemental New Drug Application (sNDA) for HETLIOZ® (tasimelteon) aimed at treating jet lag disorder. This follows a Complete Response Letter from the FDA received on August 19, 2019. Vanda submitted a hearing request on July 1, 2022, disputing the FDA's findings on the efficacy of their studies. The company remains committed to gaining approval for HETLIOZ® to address an unmet medical need.
Vanda Pharmaceuticals Inc. (VNDA) announced Q2 2022 revenues of $64.4 million, a 5% decline from Q2 2021. Net product sales for HETLIOZ® were $41.2 million (-7%), and Fanapt® sales were $23.2 million (-1%). The company reported a net income of $2.6 million, down from $9.7 million in Q2 2021. For the year-to-date, total revenues of $124.6 million also reflect a 5% decrease. Vanda expects total revenues for 2022 to range from $240 million to $280 million.
Vanda Pharmaceuticals (Nasdaq: VNDA) plans to release its second quarter 2022 financial results on August 3, 2022, after market close. A conference call to discuss the results will be held at 4:30 PM ET on the same day. Investors can access the call via phone or through Vanda's website, where a replay will be available from 8:30 PM ET on August 3 until 8:30 PM ET on August 10. Vanda focuses on developing therapies to meet significant medical needs.
Vanda Pharmaceuticals (VNDA) announced its participation in the Jefferies 2022 Global Healthcare Conference set for June 9, 2022, at 3:30 p.m. ET in New York City. The corporate presentation will be available live on Vanda's website. Investors are encouraged to join early to ensure proper access. An archived version of the conference will be accessible on the website for approximately 30 days post-event. Vanda focuses on developing innovative therapies to meet significant medical needs and improve patient lives.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in the SLEEP 2022 conference in Charlotte, North Carolina, from June 4-8, 2022. On June 7, scientific presentations will focus on topics such as genetic aberrations linked to sleep disturbances and observational studies on sleep-wake phase disorders. Key presentations by Dr. Sandra Paulina Smieszek will include a novel missense variant in Melanopsin associated with delayed sleep. Vanda aims to develop innovative therapies for unmet medical needs.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) announced its participation at Digestive Disease Week (DDW) 2022, taking place from May 21-24 in San Diego, CA. The company will present two significant studies by Dr. Sandra Paulina Smieszek, Head of Genetics. The first presentation on May 21 focuses on macrophage polarization in gastroparesis, while the second on May 23 discusses the gene set enrichment analysis in Ehlers Danlos syndrome patients with gastroparesis. For more details, visit DDW's website.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported a net loss of $6.4 million for Q1 2022, a significant shift from a net income of $8.7 million in Q1 2021. Total net product sales decreased by 4% to $60.2 million, with HETLIOZ® sales down 6% to $37.0 million. The company is optimistic about expanding access to HETLIOZ® for Medicaid patients and completing the Fanapt® bipolar study by year-end. Financial guidance for 2022 is set at $240 to $280 million in total revenues, with a year-end cash expectation exceeding $440 million.
FAQ
What is the current stock price of Vanda Pharma (VNDA)?
What is the market cap of Vanda Pharma (VNDA)?
